Regulatory Index News w/c 21 October 2019

Here is a selection of this week's news from around the world

                                          

PBL given go ahead to advance anthrax vaccine to first phase

Porton Biopharma (PBL) has announced the signing of a modification to its contract with the US National Institute of Health’s National Institute of Allergy and Infectious Diseases (NIAID).

To read more follow this PharmaTimes link

 

Merck's Ebola vaccine wins key European vote

The European Medicines Agency's human drugs panel Friday supported Merck & Co.'s experimental Ebola virus vaccine, clearing the way for the European Commission to give its OK within about two months.

To read more follow this BioPharmaDive link

     
                                                                 

AstraZeneca blood cancer drug heading for showdown with AbbVie's

Blood cancer drug Calquence so far is one of the smaller sales contributors to AstraZeneca's cancer portfolio, but that could soon change if data in leukemia helps it square up to its main rival, AbbVie and Johnson & Johnson's Imbruvica.

To read more follow this BioPharmaDive link

                                                                                                                                                                                           

NHSE signs ‘definitive’ agreement for Vertex CF drugs

NHS England has announced a definitive agreement with Vertex Pharmaceuticals to make all three of their UK-licensed cystic fibrosis medicines  available - Orkambi (ivacaftor/lumacaftor), Symkevi (tezacaftor/ivacaftor) and Kalydeco (ivacaftor).

To read more follow this PharmaTimes link

     
 

Electronic prescriptions could save NHS £300m

The final phase of the NHS’ Electronic Prescription Service (EPS) roll-out is set to go live on November 18, beginning with GP practices using the TPP SystmOne system. Allegedly, the new prescription service will save the NHS £300 million by 2021.

To read more follow this PharmaTimes link

 

 

 

 

 

Lilly's 1-drug migraine business gets support with new approval

Eli Lilly on Friday won Food and Drug Administration approval for a migraine drug it acquired via a 2017 deal for CoLucid Pharmaceuticals, giving the Indianapolis pharma a partner treatment to its on-market therapy Emgality.

To read more follow this BioPharmaDive link

L O

Author

Lorna Osborn

Date Published

25th October 2019

Come and join our community!

We are ready and waiting for you

We use cookies. By continuing to browse the site or closing this message you are agreeing to our Terms and Privacy Policy

ACCEPT and Hide This Message